Skip to content
PEPLUX

Growth hormone secretagogue combination

CJC-1295 and Ipamorelin

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

CJC-1295 and Ipamorelin cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

The CJC-1295 and Ipamorelin combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is CJC-1295 and Ipamorelin?

CJC-1295 combined with ipamorelin. Whether the CJC-1295 is the form with DAC (drug affinity complex) or without DAC is not yet documented. The dispensing pharmacy must document it before this product can be ordered.

Adults who want to discuss growth hormone secretagogues with a licensed provider and who understand that CJC-1295 and ipamorelin are not FDA-approved and that the evidence in people is limited. Whether it is appropriate is a decision made with the prescriber after an evaluation, not a choice made from this page.

Key risks

  • CJC-1295 and ipamorelin are not FDA-approved, and their safety in people, alone or together, has not been established.
  • FDA's safety-risks page cites serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says available clinical data are limited.
All risks and who should not use it

FDA status

FDA status for CJC-1295 and Ipamorelin.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today.

The CJC-1295 and Ipamorelin combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

CJC-1295

No compounding pathway today.

CJC-1295, with or without DAC, is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 under a notice dated September 27, 2024, after the nominations were withdrawn, and FDA's Pharmacy Compounding Advisory Committee voted against every form it reviewed on December 4, 2024. Nothing favorable is pending.

Covers CJC-1295 with and without DAC (drug affinity complex), in every form FDA reviewed: without DAC as free base and acetate, and with DAC as free base, acetate and trifluoroacetate.

Basis
FDA's 503A categories document of September 27, 2024 removed CJC-1295 from Category 2 after its nominations were withdrawn. At its December 4, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against each form it reviewed, with and without DAC, according to the final minutes. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page cites serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says available clinical data are limited.
Checked on
October 13, 2026

Ipamorelin acetate

No compounding pathway today.

Ipamorelin is not FDA-approved, and there is no pathway for a US pharmacy or a 503B outsourcing facility to compound it today. FDA removed it from its 503A Category 2 under a notice dated September 27, 2024, after the nominations were withdrawn, and FDA's Pharmacy Compounding Advisory Committee voted against it on October 29, 2024. Ipamorelin acetate is still in FDA's 503B Category 2, the category for substances that may present significant safety risks.

Covers ipamorelin free base and ipamorelin acetate, the two forms FDA's advisory committee reviewed. FDA's 503B Category 2 entry names ipamorelin acetate.

Basis
FDA's 503A categories document of September 27, 2024 removed ipamorelin from Category 2 after its nominations were withdrawn. At its October 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted 12 to 0 against each form, with one abstention, according to the final minutes. FDA placed ipamorelin acetate in 503B Category 2 on September 29, 2023, and it remains there in the 503B categories document of March 21, 2025. It is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page cites a published report of serious adverse events, including death, when ipamorelin was given intravenously for gastric motility, and says FDA lacks sufficient information on other injectable routes. FDA's warning letter of August 24, 2026 to an online peptide seller named a tesamorelin and ipamorelin blend among unapproved new drugs.
Checked on
October 13, 2026

How it works

CJC-1295 and Ipamorelin mechanism.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a synthetic peptide that binds the ghrelin receptor, also called the growth hormone secretagogue receptor. Both act on the pituitary gland, which releases growth hormone, but through different receptors, and that difference is the usual rationale for combining them. Whether the combination does anything useful in people has not been established. CJC-1295 exists in two forms: the form with DAC (drug affinity complex) binds to albumin in the blood and stays in circulation longer than the form without DAC.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

CJC-1295 and Ipamorelin: evidence and limitations.

Published human research on each peptide is limited and short-term, and the combination has not been shown to be safe or effective in people. FDA's safety-risks page cites serious adverse events reported with each peptide. FDA placed ipamorelin acetate in its 503B Category 2, substances that may present significant safety risks, in 2023, and in 2024 FDA's Pharmacy Compounding Advisory Committee voted against adding either peptide to the 503A bulks list.

Risks

CJC-1295 and Ipamorelin risks and side effects.

  • CJC-1295 and ipamorelin are not FDA-approved, and their safety in people, alone or together, has not been established.
  • FDA's safety-risks page cites serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says available clinical data are limited.
  • FDA's safety-risks page cites a published report of serious adverse events, including death, after ipamorelin was given intravenously, and says FDA lacks sufficient information on other injectable routes, which include subcutaneous injection.
  • Medicines that raise growth hormone or IGF-1 levels can cause fluid retention, joint pain, numbness or tingling in the hands, and changes in blood glucose, and these effects may occur with these peptides.
  • Small human studies of CJC-1295 reported flushing, headache and reactions at the injection site.
  • There is no FDA label, so there is no formal list of contraindications. Growth hormone and IGF-1 promote cell growth, so these peptides should not be used with active cancer, and any past cancer needs specific review by the prescriber. They should not be used during pregnancy or breastfeeding, where there are no safety data.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • Baseline IGF-1 and other labs, and how they will be rechecked

  • Any personal history of cancer, including cancer that has been treated

  • Blood glucose, and any condition or medicine that affects it

  • Other medicines or hormones that act on the growth hormone axis

  • Heart rhythm, blood pressure and any history of fainting

  • Pregnancy, breastfeeding or plans to conceive

  • Whether an untreated medical cause or lifestyle factors better explain the reason for the request

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

Prohibited under the WADA code.

  • CJC-1295: Prohibited at all times under WADA class S2.2.4 (growth hormone releasing factors).
  • Ipamorelin acetate: Prohibited at all times under WADA class S2.2.4 (growth hormone releasing factors).

If you compete under an anti-doping authority, or are tested through your employer or federation, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.

Straight answers

Common questions about CJC-1295 and Ipamorelin.

What is the FDA status of CJC-1295 and Ipamorelin?
No compounding pathway today. CJC-1295: CJC-1295, with or without DAC, is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 under a notice dated September 27, 2024, after the nominations were withdrawn, and FDA's Pharmacy Compounding Advisory Committee voted against every form it reviewed on December 4, 2024. Nothing favorable is pending. Checked against primary sources on October 13, 2026. Ipamorelin acetate: Ipamorelin is not FDA-approved, and there is no pathway for a US pharmacy or a 503B outsourcing facility to compound it today. FDA removed it from its 503A Category 2 under a notice dated September 27, 2024, after the nominations were withdrawn, and FDA's Pharmacy Compounding Advisory Committee voted against it on October 29, 2024. Ipamorelin acetate is still in FDA's 503B Category 2, the category for substances that may present significant safety risks. Checked against primary sources on October 13, 2026.
Is compounded CJC-1295 and Ipamorelin an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. The CJC-1295 and Ipamorelin combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for CJC-1295 and Ipamorelin, and what does it not?
Published human research on each peptide is limited and short-term, and the combination has not been shown to be safe or effective in people. FDA's safety-risks page cites serious adverse events reported with each peptide. FDA placed ipamorelin acetate in its 503B Category 2, substances that may present significant safety risks, in 2023, and in 2024 FDA's Pharmacy Compounding Advisory Committee voted against adding either peptide to the 503A bulks list.
What are the risks of CJC-1295 and Ipamorelin?
CJC-1295 and ipamorelin are not FDA-approved, and their safety in people, alone or together, has not been established. The full list of side effects, and of who should not use CJC-1295 and Ipamorelin, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Why does CJC-1295 and Ipamorelin require baseline labs?
Yes. A prescriber reviews baseline labs before a first prescription of CJC-1295 and Ipamorelin. Baseline labs are included in the price.
What does CJC-1295 and Ipamorelin cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is CJC-1295 and Ipamorelin prohibited in sport?
CJC-1295: Prohibited at all times under WADA class S2.2.4 (growth hormone releasing factors). Ipamorelin acetate: Prohibited at all times under WADA class S2.2.4 (growth hormone releasing factors). If you are subject to anti-doping testing, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.
How is CJC-1295 and Ipamorelin given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

The CJC-1295 and Ipamorelin combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker